Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

相似書籍

• Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
  由: Reding, Mark T., et al.
  出版: (2020)
• Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
  由: Coyle, T E, et al.
  出版: (2014)
• Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
  由: Batt, Katharine, et al.
  出版: (2019)
• BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
  由: Lalezari, Shadan, et al.
  出版: (2019)
• Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis
  由: Lalezari, Shadan, et al.
  出版: (2020)